Ozempic stock price analysts see resistance near $127

Analysts see resistance near $127, but note any breakout could trigger technical buy signals attracting short-term momentum funds. Morgan Stanley has downgraded Novo Nordisk, whose U.S. shares are already down a third this year. That downgrade forecasts slowing demand for weight-loss drugs Ozempic and Wegovy, generic competition abroad, and trial results that may disappoint those looking for an Alzheimer’s breakthrough. The share price of Novo Nordisk, the maker of the weight-loss drug Ozempic, has plummeted. Ozempic stock price climbed above its 20-day moving average, signaling renewed momentum after last week’s consolidation. Market-watchers suggest institutional inflows could accelerate as GLP-1 demand growth remains a global trend.